Subtype-specific sonographic signatures and clinicopathological features of metaplastic breast cancer: a 50-case cohort study

• by Boxiong Wei, Zijing Fu, Yuhong Shao, Xiuming Sun, Luzeng Chen

• July 2, 2026

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

• July 1, 2026

• 1 min

ASCO26: Michael Hassett, MD, MPH, eSyM

Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.

• July 1, 2026

• 1 min

Editorial: National Colorectal Cancer Awareness Month 2025: Current Progress and Future Prospects on Colorectal Cancer Prevention, Diagnosis and Treatment

• by Passardi, Alessandro, Gurzu, Simona, Gibbons, David, Ricciardi, Rocco

• July 2, 2026